Logos Biosystems Signed an Agreement to Develop a Blood Cell Analysis System

May 31, 2020

Logos Biosystems Signed an Agreement to Develop a Blood Cell Analysis System


Logos Biosystems announced on May 29th that they have signed an agreement to develop a blood cell analysis system based on machine learning image analysis for residual blood cancer cell testing.

Logos Biosystems explained, “We have been selected as the national project supervising agency by The Ministry of Trade, Industry and Energy for the bio industry core technology development project-customized diagnostic treatment product new project and signed the agreement.”

The host organization is Logos Biosystems, and the participating organizations are Korea University Industry-Academic Cooperation Foundation and Chung-Ang University Industry-Academic Cooperation Foundation.

The project is scheduled from April 1, 2020 to December 31, 2024, and end of the 1st phase agreement will be December 31, 2022.

Logos Biosystems said, “We aim for a blood cell analysis system that can detect less than one blood cancer cell from 10,000 white blood cells." “It is a wide-use analysis system applicable for diagnosis, treatment effect, and prognosis of leukemia."

Logos Biosystems added, "It is an innovative blood cell analysis system that combines white blood cell collection and concentration based on acoustic technology, and a high-sensitivity optical system." "We are planning to develop sample pretreatment and staining reagents, an image-based analysis system capable of detecting fluorescence of at least four colors, and apply machine learning algorithms to improve reading accuracy."

The original article (Korean) here >